Cargando…

Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma

The interplay between tumor microenvironment and cancer that causes chemoresistance remains unclear. By analyzing public available microarray datasets, we identified that periostin (POSTN) was overexpressed in cancer stroma in epithelial ovarian cancer (EOC) patients. Immunohistochemistry analysis s...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Pi-Lin, Jan, Yi-Hua, Lin, Shih-Chieh, Huang, Chao-Cheng, Lin, Hao, Wen, Kuo-Chang, Chao, Kuan-Chong, Lai, Chiung-Ru, Wang, Peng-Hui, Chuang, Chi-Mu, Wu, Hua-Hsi, Twu, Nae-Fang, Yen, Ming-Shyen, Hsiao, Michael, Huang, Chi-Ying F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826188/
https://www.ncbi.nlm.nih.gov/pubmed/26716408
http://dx.doi.org/10.18632/oncotarget.6700
Descripción
Sumario:The interplay between tumor microenvironment and cancer that causes chemoresistance remains unclear. By analyzing public available microarray datasets, we identified that periostin (POSTN) was overexpressed in cancer stroma in epithelial ovarian cancer (EOC) patients. Immunohistochemistry analysis showed overexpression of stromal POSTN is a powerful independent poor prognostic predictor for EOC patients. Furthermore, patients with high levels of stromal POSTN tend to have higher percentage of cisplatin resistance compared to those with low levels of stromal POSTN. Moreover, we found POSTN treatment can induce cisplatin resistant and activate AKT pathway in A2780 cells in vitro. Inhibition of AKT activity by AKT inhibitor MK-2206 abolished POSTN-induced AKT activation and cisplatin resistance in vitro. Taken together, we found high POSTN expression in cancer microenvironment is correlated with poor prognosis in EOC patients and associated with platinum resistance. The effect of POSTN in cancer stroma cells may activate AKT pathway in tumor and AKT inhibitor can be beneficial to augment the efficacy of existing cancer therapeutics.